| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acknowledgements
|
|
|
|
31 |
S1 |
p. vii
|
article
|
| 2 |
Editorial Board
|
|
|
|
31 |
S1 |
p. i
|
article
|
| 3 |
Journal Information
|
|
|
|
31 |
S1 |
p. ii
|
article
|
| 4 |
17O A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors
|
Sato, J.
|
|
|
31 |
S1 |
p. S5-S6
|
article
|
| 5 |
19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)
|
Bedard, P.
|
|
|
31 |
S1 |
p. S7
|
article
|
| 6 |
18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
|
Hollebecque, A.
|
|
|
31 |
S1 |
p. S6
|
article
|
| 7 |
1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)
|
Le Tourneau, C.
|
|
|
31 |
S1 |
p. S1
|
article
|
| 8 |
16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
|
Moreno, V.
|
|
|
31 |
S1 |
p. S5
|
article
|
| 9 |
13P A mitigation of breast cancer-induced immune-suppressive tumor microenvironment through curbing miR-155/IL-10/TNF-α loop using a novel quercetin derivative
|
Youness, R.A.
|
|
|
31 |
S1 |
p. S4
|
article
|
| 10 |
30P Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer
|
Gkountakos, A.
|
|
|
31 |
S1 |
p. S10
|
article
|
| 11 |
5P Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents
|
Tarantino, P.
|
|
|
31 |
S1 |
p. S1-S2
|
article
|
| 12 |
31P A study to assess the efficacy and feasibility of adding pioglitazone to imatinib in patients of CML with suboptimal response in a resource-limited setting
|
Goyal, S.
|
|
|
31 |
S1 |
p. S10
|
article
|
| 13 |
27P CD73 promotes pancreatic cancer cell progression through TNFR2/AKT and ERK signaling
|
Zhou, L.
|
|
|
31 |
S1 |
p. S9
|
article
|
| 14 |
14P Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients
|
Castanon Alvarez, E.
|
|
|
31 |
S1 |
p. S4
|
article
|
| 15 |
25P Development of new therapeutic drugs for pancreatic cancer targeting choline transporter-like protein 1 (CTL1/SLC44A1)
|
Inazu, M.
|
|
|
31 |
S1 |
p. S8-S9
|
article
|
| 16 |
36P Eligibility and outcomes in phase I clinical trials testing targeted therapy, immunotherapy and combinations: A single-institution study
|
Marra, A.
|
|
|
31 |
S1 |
p. S13
|
article
|
| 17 |
32P Evaluation of novel hypoxia-selective antitumor agents blocking HIF-1α/CA9 axis in breast cancer
|
Buravchenko, G.I.
|
|
|
31 |
S1 |
p. S11
|
article
|
| 18 |
29P FGFR1-4 high mRNA expression (mRNAh) as predictive biomarker for FGFR inhibitors in breast cancer (BC)
|
Hierro, C.
|
|
|
31 |
S1 |
p. S9-S10
|
article
|
| 19 |
26P Genome-wide virus-integration map reveals a common oncogenic insertional mechanism of HPV, HBV, and EBV
|
Tian, R.
|
|
|
31 |
S1 |
p. S9
|
article
|
| 20 |
12P IL-18 improves the anti-cancer immunity of human gamma delta T cells against prostate cancer
|
Nada, M.H.
|
|
|
31 |
S1 |
p. S3-S4
|
article
|
| 21 |
20P Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma
|
Awada, G.
|
|
|
31 |
S1 |
p. S7
|
article
|
| 22 |
10P In vitro and in vivo cytolethal and antitumor effects of a novel fusion protein targeting IL-24 toward breast cancer cells
|
Jahanian-Najafabadi, A.
|
|
|
31 |
S1 |
p. S2
|
article
|
| 23 |
24P L1CAM as a candidate therapeutic target in small-cell neuroendocrine prostate cancer
|
Corella, A.N.
|
|
|
31 |
S1 |
p. S8
|
article
|
| 24 |
23P Novel ERα degrader, 3,20(R)-dihydroxy-19-norpregnatriene, inhibits MCF-7 cell growth through p21/CDK2/CDK4 pathway
|
Scherbakov, A.M.
|
|
|
31 |
S1 |
p. S8
|
article
|
| 25 |
21P OX401, a new generation of PARP-interfering drug for cancer treatment
|
Jdey, W.
|
|
|
31 |
S1 |
p. S8
|
article
|
| 26 |
34P Pharmacogenomics of docetaxel response in prostate cancer: A precision medicine initiative
|
Grover, A.
|
|
|
31 |
S1 |
p. S12
|
article
|
| 27 |
11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
|
Angevin, E.
|
|
|
31 |
S1 |
p. S3
|
article
|
| 28 |
7P Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
|
Prado Vázquez, G.
|
|
|
31 |
S1 |
p. S2
|
article
|
| 29 |
6P Targeting leukemic stem cells using humanized chimeric immunotoxin
|
Jayaprakasam, M.
|
|
|
31 |
S1 |
p. S2
|
article
|
| 30 |
35P The application of radiomics-based machine learning in the differential diagnosis between atypical low-grade astrocytoma and anaplastic astrocytoma
|
Wang, M.
|
|
|
31 |
S1 |
p. S12
|
article
|
| 31 |
37P The CellMiner and CellMinerCDB web-applications as a base for pharmacogenomics
|
Reinhold, W.
|
|
|
31 |
S1 |
p. S13
|
article
|
| 32 |
42P The establishment of a large tumor organoid biobank using a well characterized/annotated patient-derived xenograft (PDX) library to enable drug discovery and translational research
|
Bourre, L.
|
|
|
31 |
S1 |
p. S13-S14
|
article
|
| 33 |
40P The exosomes transfer the acquired resistance of MCF-7 breast cancer cells to rapamycin and tamoxifen
|
Scherbakov, A.M.
|
|
|
31 |
S1 |
p. S13
|
article
|
| 34 |
Society Pages
|
|
|
|
31 |
S1 |
p. v-vi
|
article
|
| 35 |
Table of Contents
|
|
|
|
31 |
S1 |
p. iv
|
article
|
Journal description